Recent advances in self-adjuvanting glycoconjugate vaccines

Akira, 2001, Toll-like receptors: critical proteins linking innate and acquired immunity, Nat Immunol, 2, 675, 10.1038/90609 Palm, 2009, Pattern recognition receptors and control of adaptive immunity, Immunol Rev, 227, 221, 10.1111/j.1600-065X.2008.00731.x Coffman, 2010, Vaccine adjuvants: putting innate immunity to work, Immunity, 33, 492, 10.1016/j.immuni.2010.10.002 Jackson, 2004, A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses, Proc Natl Acad Sci U S A, 101, 15440, 10.1073/pnas.0406740101 Liu, 2013, Self-adjuvanting polymer–Peptide conjugates As therapeutic vaccine candidates against cervical Cancer, Biomacromolecules, 14, 2798, 10.1021/bm400626w Wright, 2013, Direct peptide lipidation through thiol–Ene coupling enables rapid synthesis and evaluation of self-adjuvanting vaccine candidates, Angew Chem Int Ed, 52, 10616, 10.1002/anie.201305620 Zom, 2014, Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–Peptide conjugates, Cancer Immunol Res, 2, 756, 10.1158/2326-6066.CIR-13-0223 Skwarczynski, 2016, Peptide-based synthetic vaccines, Chem Sci, 7, 842, 10.1039/C5SC03892H Lu, 2020, Synthesis and evaluation of novel TLR2 agonists as potential adjuvants for Cancer vaccines, J Med Chem, 63, 2282, 10.1021/acs.jmedchem.9b01044 Skwarczynski, 2020, Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines, Sci Adv, 6, eaax2285, 10.1126/sciadv.aax2285 Singh, 1999, Advances in vaccine adjuvants, Nat Biotechnol, 17, 1075, 10.1038/15058 Petrovsky, 2004, Vaccine adjuvants: current state and future trends, Immunol Cell Biol, 82, 488, 10.1111/j.0818-9641.2004.01272.x Guy, 2007, The perfect mix: recent progress in adjuvant research, Nat Rev Microbiol, 5, 396, 10.1038/nrmicro1681 Gupta, 1998, Aluminum compounds as vaccine adjuvants, Adv Drug Del Rev, 32, 155, 10.1016/S0169-409X(98)00008-8 Marrack, 2009, Towards an understanding of the adjuvant action of aluminium, Nat Rev Immunol, 9, 287, 10.1038/nri2510 Kool, 2012, Alum adjuvant: some of the tricks of the oldest adjuvant, J Med Microbiol, 61, 927, 10.1099/jmm.0.038943-0 Eisenbarth, 2008, Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants, Nature, 453, 1122, 10.1038/nature06939 Hornung, 2008, Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization, Nat Immunol, 9, 847, 10.1038/ni.1631 Kuroda, 2011, Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms, Immunity, 34, 514, 10.1016/j.immuni.2011.03.019 Marichal, 2011, DNA released from dying host cells mediates aluminum adjuvant activity, Nat Med, 17, 996, 10.1038/nm.2403 Schultze, 2008, Safety of MF59™ adjuvant, Vaccine, 26, 3209, 10.1016/j.vaccine.2008.03.093 Garçon, 2012, Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion, Expert Rev Vaccines, 11, 349, 10.1586/erv.11.192 O’Hagan, 2012, The mechanism of action of MF59 – an innately attractive adjuvant formulation, Vaccine, 30, 4341, 10.1016/j.vaccine.2011.09.061 Cluff, 2010, Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results, Adv Exp Med Biol, 667, 111, 10.1007/978-1-4419-1603-7_10 Mata-Haro, 2007, The vaccine adjuvant monophosphoryl lipid a as a TRIF-Biased agonist of TLR4, Science, 316, 1628, 10.1126/science.1138963 Casella, 2008, Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant, Cell Mol Life Sci, 65, 3231, 10.1007/s00018-008-8228-6 Krieg, 1995, CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, 374, 546, 10.1038/374546a0 Hemmi, 2000, A toll-like receptor recognizes bacterial DNA, Nature, 408, 740, 10.1038/35047123 Krieg, 2002, CpG motifs in bacterial DNA and their immune effects, Annu Rev Immunol, 20, 709, 10.1146/annurev.immunol.20.100301.064842 Krieg, 2006, Therapeutic potential of Toll-like receptor 9 activation, Nat Rev Drug Discov, 5, 471, 10.1038/nrd2059 Takeda, 2005, Toll-like receptors in innate immunity, Int Immunol, 17, 1, 10.1093/intimm/dxh186 Takeuchi, 2001, Discrimination of bacterial lipoproteins by Toll-like receptor 6, Int Immunol, 13, 933, 10.1093/intimm/13.7.933 Luo, 2016, The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease, AAPS J, 18, 1562, 10.1208/s12248-016-9979-x Spohn, 2004, Synthetic lipopeptide adjuvants and Toll-like receptor 2–structure-activity relationships, Vaccine, 22, 2494, 10.1016/j.vaccine.2003.11.074 Bessler, 1984, The mitogenic principle of Escherichiacoli lipoprotein: B-lymphocyte mitogenicity of the synthetic analogue Palmitoyl-tetrapeptide (PAM-SER-SER-ASN-ALA), Biochem Biophys Res Commun, 121, 55, 10.1016/0006-291X(84)90687-9 Jung, 1983, The mitogenic principle of Escherichia coli lipoprotein: synthesis, spectroscopic characterization, and mitogenicity of N-Palmitoyl-S-[(2R,)-2,3-dipalmitoyloxypropyl]-(R)-cysteine methyl ester, Liebigs Ann Chem, 1983, 1608, 10.1002/jlac.198319830916 Jin, 2007, Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide, Cell, 130, 1071, 10.1016/j.cell.2007.09.008 Spohn, 2004, Synthetic lipopeptide adjuvants and Toll-like receptor 2—structure–activity relationships, Vaccine, 22, 2494, 10.1016/j.vaccine.2003.11.074 Opal, 1999, Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock, J Infect Dis, 180, 1584, 10.1086/315093 Poltorak, 1998, Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene, Science, 282, 2085, 10.1126/science.282.5396.2085 Hayashi, 2001, The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5, Nature, 410, 1099, 10.1038/35074106 Uematsu, 2006, Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells, Nat Immunol, 7, 868, 10.1038/ni1362 Alexopoulou, 2001, Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3, Nature, 413, 732, 10.1038/35099560 Diebold, 2004, Reis e Sousa c. Innate antiviral responses by means of TLR7-Mediated recognition of single-stranded RNA, Science, 303, 1529, 10.1126/science.1093616 Heil, 2004, Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8, Science, 303, 1526, 10.1126/science.1093620 Lund, 2004, Recognition of single-stranded RNA viruses by Toll-like receptor 7, Proc Natl Acad Sci U S A, 101, 5598, 10.1073/pnas.0400937101 Chamaillard, 2003, An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid, Nat Immunol, 4, 702, 10.1038/ni945 Girardin, 2003, Nod2 is a general sensor of peptidoglycan through Muramyl Dipeptide (MDP) detection, J Biol Chem, 278, 8869, 10.1074/jbc.C200651200 Inohara, 2003, NODs: intracellular proteins involved in inflammation and apoptosis, Nat Rev Immunol, 3, 371, 10.1038/nri1086 Inohara, 2003, Host recognition of bacterial muramyl dipeptide mediated through NOD2: IMPLICATIONS FOR CROHN′S DISEASE, J Biol Chem, 278, 5509, 10.1074/jbc.C200673200 Inohara, 2005, NOD-LRR PROTEINS: Role in Host-Microbial Interactions and Inflammatory Disease, Annu Rev Biochem, 74, 355, 10.1146/annurev.biochem.74.082803.133347 Kanneganti, 2007, Intracellular NOD-like receptors in host defense and disease, Immunity, 27, 549, 10.1016/j.immuni.2007.10.002 Timmermans, 2013, Blueprints of signaling interactions between pattern recognition receptors: implications for the design of vaccine adjuvants, Clin Vaccine Immunol, 20, 427, 10.1128/CVI.00703-12 Albin, 2019, Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses, ACS Cent Sci, 5, 1137, 10.1021/acscentsci.8b00823 Zom, 2019, Dual synthetic peptide conjugate vaccine simultaneously triggers TLR2 and NOD2 and activates human dendritic cells, Bioconjugate Chem, 30, 1150, 10.1021/acs.bioconjchem.9b00087 Takenori Natori, 1993, Agelasphins, novel α-galactosylceramides from the marine sponge Agelas mauritianus, Tetrahedron Lett, 34, 5591, 10.1016/S0040-4039(00)73889-5 Morita, 1995, Structure-activity relationship of. alpha.-Galactosylceramides against B16-Bearing mice, J Med Chem, 38, 2176, 10.1021/jm00012a018 Kawano, 1997, CD1d-restricted and TCR-Mediated activation of Vα14 NKT cells by glycosylceramides, Science, 278, 1626, 10.1126/science.278.5343.1626 Kamada, 2001, Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to Vα14 NKT cells, Int Immunol, 13, 853, 10.1093/intimm/13.7.853 Tashiro, 2010, Fifteen years since the development of KRN7000 – structure-activity relationship studies on novel glycosphingolipids which stimulate natural killer t cells, Trends Glycosci Glycotechnol, 22, 280, 10.4052/tigg.22.280 Pichichero, 2013, Protein carriers of conjugate vaccines: characteristics, development, and clinical trials, Hum Vaccin Immunother, 9, 2505, 10.4161/hv.26109 Schutze, 1985, Carrier-induced epitopic suppression, a major issue for future synthetic vaccines, J Immunol, 135, 2319, 10.4049/jimmunol.135.4.2319 Findlow, 2016, Interactions of conjugate vaccines and co-administered vaccines, Hum Vacc Immunother, 12, 226, 10.1080/21645515.2015.1091908 Pinho, 2015, Glycosylation in cancer: mechanisms and clinical implications, Nat Rev Cancer, 15, 540, 10.1038/nrc3982 Gold, 1975, Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants, J Clinic Invest, 56, 1536, 10.1172/JCI108235 Käyhty, 1984, Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory, Pediatrics, 74, 857, 10.1542/peds.74.5.857 O’Brien, 1996, Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines, Pediatr Infect Dis J, 15, 425, 10.1097/00006454-199605000-00009 Guttormsen, 1999, Cognate stimulatory B-Cell–T-Cell interactions are critical for T-Cell help recruited by glycoconjugate vaccines, Infect Immun, 67, 6375, 10.1128/IAI.67.12.6375-6384.1999 Gandhi, 2016, Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®), Postgrad Med, 28, 548, 10.1080/00325481.2016.1203238 Fujimoto, 2009, Lipopeptides from Staphylococcus aureus as Tlr2 Ligands: prediction with mrna expression, chemical synthesis, and immunostimulatory activities, Chembiochem, 10, 2311, 10.1002/cbic.200900242 Azuma, 2010, The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation, PLoS One, 5, 10.1371/journal.pone.0012550 Sawahata, 2011, Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2, Microb Infect, 13, 350, 10.1016/j.micinf.2010.12.003 Toyokuni, 1994, Synthetic vaccines: synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins, J Am Chem Soc, 116, 395, 10.1021/ja00080a055 Buskas, 2005, Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen, Angew Chem Int Ed, 44, 5985, 10.1002/anie.200501818 Ingale, 2007, Robust immune responses elicited by a fully synthetic three-component vaccine, Nat Chem Biol, 3, 663, 10.1038/nchembio.2007.25 Leclerc, 1991, Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1, J Virol, 65, 711, 10.1128/jvi.65.2.711-718.1991 Lakshminarayanan, 2012, Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine, Proc Natl Acad Sci U S A, 109, 261, 10.1073/pnas.1115166109 Thompson, 2015, Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide, Chem Commun, 51, 10214, 10.1039/C5CC02199E Kaiser, 2010, Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the toll-like receptor 2, Angew Chem Int Ed, 49, 3688, 10.1002/anie.201000462 Cai, 2013, Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells, Chem Eur J, 19, 1962, 10.1002/chem.201203709 Cai, 2013, Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-Cell epitopes from tetanus toxoid, Angew Chem Int Ed, 52, 6106, 10.1002/anie.201300390 Palitzsch, 2014, A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-Helper-Cell epitopes, Angew Chem Int Ed, 53, 14245, 10.1002/anie.201406843 Chang, 2018, Syntheses and Immunological Evaluation of Self-Adjuvanting Clustered N-Acetyl and N-Propionyl Sialyl-Tn Combined with a T-helper Cell Epitope as Antitumor Vaccine Candidates, Angew Chem Int Ed, 57, 8219, 10.1002/anie.201804437 Holmberg, 2004, Vaccination with Theratope (STn-KLH) as treatment for breast cancer, Expert Rev Vaccines, 3, 655, 10.1586/14760584.3.6.655 Feng, 2019, Syntheses and functional studies of self-adjuvanting Anti-HER2 Cancer vaccines, Chem Asian J, 14, 4268, 10.1002/asia.201901002 Khan, 2009, Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells, Mol Immunol, 46, 1084, 10.1016/j.molimm.2008.10.006 Wilkinson, 2011, Self-adjuvanting multicomponent Cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the toll-like receptor 2 agonist Pam3CysSer, Angew Chem Int Ed, 50, 1635, 10.1002/anie.201006115 Wilkinson, 2012, Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates, Chem Eur J, 18, 16540, 10.1002/chem.201202629 McDonald, 2014, Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates, Chem Commun, 50, 10273, 10.1039/C4CC03510K Ashhurst, 2019, Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against Mycobacterium tuberculosis, J Med Chem, 62, 8080, 10.1021/acs.jmedchem.9b00832 Xu, 2020, J Control Release, 317, 96, 10.1016/j.jconrel.2019.11.018 McDonald, 2018, Synthesis of a self-adjuvanting MUC1 vaccine via diselenide-selenoester ligation-deselenization, ACS Chem Biol, 13, 3279, 10.1021/acschembio.8b00675 Wang, 2012, Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse, ACS Chem Biol, 7, 235, 10.1021/cb200358r Zhou, 2014, Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers, Org Biomol Chem, 12, 3238, 10.1039/C4OB00390J Liao, 2016, Fully Synthetic Self-Adjuvanting alpha-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis, ACS Cent Sci, 2, 210, 10.1021/acscentsci.5b00364 Wang, 2017, Synthesis and immunological comparison of differently linked lipoarabinomannan oligosaccharide-monophosphoryl lipid a conjugates as antituberculosis vaccines, J Org Chem, 82, 12085, 10.1021/acs.joc.7b01817 Park, 2009, The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex, Nature, 458, 1191, 10.1038/nature07830 Zamyatina, 2018, Aminosugar-based immunomodulator lipid a: synthetic approaches, Beilstein J Org Chem, 14, 25, 10.3762/bjoc.14.3 Kusumoto, 2007, Synthesis of endotoxic principle of bacterial lipopolysaccharide and its recognition by the innate immune systems of hosts, Chem Rec, 6, 333, 10.1002/tcr.20098 Molinaro, 2014, Chemistry of lipid a: At the heart of innate immunity, Chem Eur J, 21, 500, 10.1002/chem.201403923 Gao, 2018, Progress in the synthesis and biological evaluation of lipid A and its derivatives, Med Res Rev, 38, 556, 10.1002/med.21447 Lewicky, 2016, Synthesis of a TLR4 agonist-carbohydrate antigen conjugate As a self-adjuvanting Cancer vaccine, ChemistrySelect, 1, 906, 10.1002/slct.201600230 Cavallari, 2014, A semisynthetic carbohydrate-lipid vaccine that protects against S. Pneumoniae in mice, Nat Chem Biol, 10, 950, 10.1038/nchembio.1650 Anderson, 2015, NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity, Chem Sci, 6, 5120, 10.1039/C4SC03599B Compton, 2015, Synthesis and activity of 6″-Deoxy-6″-thio-α-GalCer and peptide conjugates, Org Lett, 17, 5954, 10.1021/acs.orglett.5b02836 Yin, 2017, IgG antibody response elicited by a fully synthetic two-component carbohydrate-based Cancer vaccine candidate with α-Galactosylceramide as built-in adjuvant, Org Lett, 19, 456, 10.1021/acs.orglett.6b03591 Chen, 2020, Fully synthetic invariant NKT cell-dependent self-adjuvanting antitumor vaccines eliciting potent immune response in mice, Mol Pharm, 17, 417 Gential, 2019, Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7, Bioorg Med Chem Lett, 29, 1340, 10.1016/j.bmcl.2019.03.048 De Silva, 2009, Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on tn−PS A1 conjugates, J Am Chem Soc, 131, 9622, 10.1021/ja902607a Berti, 2013, Recent mechanistic insights on glycoconjugate vaccines and future perspectives, ACS Chem Biol, 8, 1653, 10.1021/cb400423g Shi, 2016, Sialyl-tn polysaccharide A1 as an entirely carbohydrate immunogen: synthesis and immunological evaluation, J Am Chem Soc, 138, 14264, 10.1021/jacs.6b05675 Galili, 1988, Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells, J Biol Chem, 263, 17755, 10.1016/S0021-9258(19)77900-9 Galili, 1984, A unique natural human IgG antibody with anti-alpha-galactosyl specificity, J Exp Med, 160, 1519, 10.1084/jem.160.5.1519 Deguchi, 2010, Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express α-Gal epitopes: a novel approach to immunotherapy in pancreatic Cancer, Cancer Res, 70, 5259, 10.1158/0008-5472.CAN-09-4313 LaTemple, 1999, Increased immunogenicity of tumor vaccines complexed with anti-gal: studies in knockout mice for α1,3Galactosyltransferase, Cancer Res, 59, 3417 Masahiro, 2013, Role of α‐gal epitope/anti‐Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer, Cancer Sci, 104, 282, 10.1111/cas.12084 Rossi, 2005, Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-Galactosyl epitopes, Cancer Res, 65, 10555, 10.1158/0008-5472.CAN-05-0627 LaTemple, 1996, Synthesis of α-Galactosyl epitopes by recombinant α1,3Galactosyltransferase for opsonization of human tumor cell vaccines by anti-galactose, Cancer Res, 56, 3069 Tanemura, 2013, Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer, Cancer Sci, 104, 282, 10.1111/cas.12084 LaTemple, 1996, Synthesis of α-Galactosyl epitopes by recombinant α1,3Galactosyltransferase for opsonization of human tumor cell vaccines by anti-galactose, Cancer Res, 56, 3069 Iniguez, 2017, An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major, PLoS Neglect Trop D, 11, 10.1371/journal.pntd.0006039 Miyoshi E, Fukase K, Manabe Y, Takamatsu S, Tanemura M. Japan Patent Application No2014-263056 2014. Rostovtsev, 2002, A stepwise huisgen cycloaddition process: copper(I)-Catalyzed regioselective “Ligation” of azides and terminal alkynes, Angew Chem Int Ed, 41, 2596, 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4 Tornøe, 2002, Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regiospecific copper(I)-Catalyzed 1,3-Dipolar cycloadditions of terminal alkynes to azides, J Org Chem, 67, 3057, 10.1021/jo011148j Kent, 2009, Total chemical synthesis of proteins, Chem Soc Rev, 38, 338, 10.1039/B700141J Pattabiraman, 2011, Rethinking amide bond synthesis, Nature, 480, 471, 10.1038/nature10702 Ingale, 2006, Synthesis of Glyco(lipo)peptides by liposome-mediated native chemical ligation, Org Lett, 8, 5785, 10.1021/ol062423x Ingale, 2009, Increasing the antigenicity of synthetic tumor‐associated carbohydrate antigens by targeting toll‐like receptors, ChemBioChem, 10, 455, 10.1002/cbic.200800596 Du, 2019, Liposomal antitumor vaccines targeting mucin 1 elicit a lipid‐dependent immunodominant response, Chem Asian J, 14, 2116, 10.1002/asia.201900448